PFIZER WKN: 852009 ISIN: US7170811035 Forum: Aktien Thema: Hauptdiskussion

Frida, du kannst es mit dem Google Translate übersetzen. Bissl sich bemühen

Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants 03.09.2022 PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is the first oral therapy specifically designed to combat COVID-19 to be evaluated in a pediatric clinical study PAXLOVID is currently authorized under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) in both high-risk adult and high-risk pediatric patients 12 years of age and older weighing at least 40 kg Clinical data from the EPIC-HR study showed PAXLOVID reduced risk of hospitalization or death from any cause by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo, with no deaths observed in the treatment group. Treatment-emergent adverse events were comparable between PAXLOVID (23%) and placebo (24%), most of which were mild in intensity.

😆

Immer diese Q Leute🤣

😄 geil bringt mal ne vernünftige Quelle - bitte - danke

Oxebanane.... geht das auch auf deutsch

Blablabla

Pfizer könnte ab heute weiter steigen - nach der Rede, in der Biden Pfizer mehrfach explizit positiv erwähnt hat. https://www.youtube.com/watch?v=5dOXom8uLYg&t=3788s

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women 03.02.2022 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06482077 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women. The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants. Pfizer will publish outcomes from this clinical trial at a future date

Aber das ist doch eine gute Nachricht oder verstehe ich das falsch....

Altes

Amts Kackding, ich warte auf eine Gelegenheit und dann werde ich leider meinen Verlusttopf erhöhen!!